Highest-materiality recent filing
Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25
Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.
Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024
Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).
Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference
Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.
Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA
Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.
Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed
Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.
Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M
Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.
Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance
Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.
Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair
Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.
Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix
GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).
Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline
Acquisition completed for ~$935M cash; $8.55 per share.
Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge
Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.
Jazz Pharmaceuticals to acquire Chimerix for $8.55/share in all-cash tender offer
Tender offer to commence by March 24, 2025; Chimerix board unanimously recommends.
Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone
All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.
Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B
Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.
Jazz CEO Bruce Cozadd to retire by end of 2025; company to search for successor
Bruce Cozadd notified Board of intent to retire as CEO upon appointment of successor.
Jazz Pharmaceuticals receives FDA accelerated approval for Ziihera in HER2+ biliary tract cancer
FDA approved Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.
Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B
Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.
Jazz Prices $1B 3.125% Exchangeable Notes Due 2030, Preps $500M Loan Repayment & $150M Buyback
$1.0B aggregate principal of 3.125% exchangeable senior notes due 2030, including $150M overallotment exercised.
Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%
On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.
Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher
Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
On May 31, 2024, Catherine Sohn, Pharm.D. notified the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), that she is retiring and will not stand for re-election to the Board, when her term expires, at the Company’s 2024 annual general meeting of shareholders.
Max materiality 0.88 · Median 0.75 · Most common event earnings